Aarti Pharmalabs Limited — Investor Meet, 01-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Aarti Pharmalabs reported Q4 FY26 revenue of Rs.580 Cr (+9% YoY) and FY26 revenue of Rs.1798 Cr. Full-year PAT was Rs.176 Cr, impacted by a Rs.33 Cr forex loss. A final dividend of Rs.2/share was declared.

Xanthine derivatives and CDMO hit record quarterly revenues. Xanthine capacity is expanding to 9,000 MTPA, aiming for over Rs.1000 Cr revenue. CDMO grew 32% YoY in FY26, with 40-50% projected growth for FY27, targeting USD 100 million (approx. Rs.830 Cr). API business expects to surpass FY25 revenues in FY27.

With Rs.400 Cr capex in FY26 and similar plans for FY27, the company targets 15-18% revenue and EBITDA growth over 3-4 years, projecting a confident business outlook.